Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Ensysce acquires Cy Biopharma for $77 million

PUBLIC · ENSCAug 07, 2026•2 days ago

Acquiring Company

Ensysce Biosciences

Acquired Company

Cy Biopharma

New YorkManufacturingHardwareFinancial ServicesFinanceFintechLendingBankingBiotechnologyHealth CarePharmaceuticalBiopharma

Description

Ensysce Biosciences has acquired Cy Biopharma for USD 77 million to enhance its pain therapeutics portfolio. With this acquisition, Ensysce shifts from an opioid focus to include neuroplastogenic therapies for complex regional pain syndrome. Former Cy shareholders will hold approximately 75% of the combined entity, effectively integrating Cy's pipeline into Ensysce.

Company Information

Company

Ensysce Biosciences

Location

Support@Grasshopperbank

New York, United States

About

Ensysce Biosciences, based in San Diego, CA is a clinical-stage biotech company using its two novel proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPARTM) platforms, the Company is seeking to develop next-generation, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio encompassing a wide array of prescription drugs. For more information, please visit www.ensysce.com.

Related People

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Ensysce Biosciences's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.